AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALDX
  4. [8-K] Aldeyra Therapeutics, Inc. Reports Material Event

[8-K] Aldeyra Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock ALDX logo
Aldeyra Therapeu

NASDAQ:ALDX

ALDX Rankings

#3667 Ranked by Market Cap
N/A Ranked by Dividends

ALDX Latest News

Aug 19, 2025
Aldeyra Therapeutics Receives Fast Track Designation for ADX�2191 for the Treatment of Retinitis Pigmentosa
Aug 6, 2025
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Jul 24, 2025
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
Jul 17, 2025
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Jun 26, 2025
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

ALDX Latest SEC Filings

Aug 19, 2025
[8-K] Aldeyra Therapeutics, Inc. Reports Material Event
Aug 15, 2025
[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity
Aug 14, 2025
[SCHEDULE 13G/A] Aldeyra Therapeutics, Inc. SEC Filing
Aug 13, 2025
[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity
Aug 12, 2025
[144] Aldeyra Therapeutics, Inc. SEC Filing

ALDX Stock Data

323.65M
53.17M
3.13%
56.85%
7.73%
Biotechnology
Pharmaceutical Preparations
United States
LEXINGTON